Activated protein C resistance in the absence of factor V Leiden mutation is associated with an increased risk of thrombotic complications in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

HAEMA

Volumn 8, Issue 1, 2005, Pages 118-120

  Abdelkefi, Abderrahman ^a   Romdhane, Neila Ben ^b   Younes, Mohamed ^c   Guermazi, Sami ^d  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^d PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Activated protein C resistance; Deep vein thrombosis; Myeloma; Thalidomide; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DEXAMETHASONE; THALIDOMIDE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; LUNG EMBOLISM; LUNG SCINTISCANNING; MULTIPLE MYELOMA; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; THROMBOSIS;

EID: 15244341769     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 2: 4319-4323.
2. Weber D. Rankin K, Gavino Med M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
3. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
4. Cavo M, Zamagni E, Cellini C et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272-2273.
5. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
6. Belin Santos A, Llamas P, Roman A et al. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol 2003; 122: 159-160.
7. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinol 2002; 13: 187-192.